• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
What is the current status of Japan's efforts to meet global goals and targets to eliminate cervical cancer?日本在实现消除宫颈癌的全球目标方面所做努力的现状如何?
Glob Health Med. 2021 Feb 28;3(1):44-47. doi: 10.35772/ghm.2020.01070.
2
The projected timeframe until cervical cancer elimination in Australia: a modelling study.澳大利亚消除宫颈癌的预计时间框架:建模研究。
Lancet Public Health. 2019 Jan;4(1):e19-e27. doi: 10.1016/S2468-2667(18)30183-X. Epub 2018 Oct 2.
3
Tracking the global spread of vaccine sentiments: the global response to Japan's suspension of its HPV vaccine recommendation.追踪疫苗情绪的全球传播:全球对日本暂停人乳头瘤病毒疫苗推荐的反应。
Hum Vaccin Immunother. 2014;10(9):2543-50. doi: 10.4161/21645515.2014.969618. Epub 2014 Nov 13.
4
Human papillomavirus prevalence and type-distribution, cervical cancer screening practices and current status of vaccination implementation in Russian Federation, the Western countries of the former Soviet Union, Caucasus region and Central Asia.人乳头瘤病毒在俄罗斯联邦、前苏联西方国家、高加索地区和中亚的流行情况和型别分布、宫颈癌筛查实践以及疫苗接种实施现状。
Vaccine. 2013 Dec 31;31 Suppl 7:H46-58. doi: 10.1016/j.vaccine.2013.06.043.
5
Tuberculosis结核病
6
Mega Hpv laboratories for cervical cancer control: Challenges and recommendations from a case study of Turkey.用于宫颈癌防控的大型人乳头瘤病毒实验室:来自土耳其案例研究的挑战与建议
Papillomavirus Res. 2019 Jun;7:118-122. doi: 10.1016/j.pvr.2019.03.002. Epub 2019 Mar 13.
7
Japan's Ongoing Crisis on HPV Vaccination.日本持续的人乳头瘤病毒疫苗接种危机。
Vaccines (Basel). 2020 Jul 6;8(3):362. doi: 10.3390/vaccines8030362.
8
Impact of HPV vaccine hesitancy on cervical cancer in Japan: a modelling study.HPV 疫苗犹豫对日本宫颈癌的影响:建模研究。
Lancet Public Health. 2020 Apr;5(4):e223-e234. doi: 10.1016/S2468-2667(20)30010-4. Epub 2020 Feb 10.
9
Cost-effectiveness analysis of a quadrivalent human papilloma virus vaccine in Mexico.四价人乳头瘤病毒疫苗在墨西哥的成本效益分析。
Arch Med Res. 2009 Aug;40(6):503-13. doi: 10.1016/j.arcmed.2009.08.004.
10
The Road to Cervical Cancer Elimination消除宫颈癌之路

引用本文的文献

1
Development of an intervention to increase HPV vaccine uptake in Colombia.在哥伦比亚开发一项提高人乳头瘤病毒(HPV)疫苗接种率的干预措施。
Pilot Feasibility Stud. 2025 May 31;11(1):74. doi: 10.1186/s40814-025-01609-5.
2
Cost-effectiveness analysis of 9-valent human papillomavirus vaccine combined with screening for cervical cancer in Japan.日本9价人乳头瘤病毒疫苗联合宫颈癌筛查的成本效益分析
Int J Gynaecol Obstet. 2025 May;169(2):788-801. doi: 10.1002/ijgo.16125. Epub 2024 Dec 28.
3
Impact of financial literacy and education on breast and cervical cancer screening participation in Japan.金融知识和教育对日本乳腺癌和宫颈癌筛查参与度的影响。
PLoS One. 2024 Nov 13;19(11):e0313687. doi: 10.1371/journal.pone.0313687. eCollection 2024.
4
Risk factors for positive cervical cytology during early pregnancy screening and awareness of positive cytological results in Japan: a report from the Pregnant Women Health Initiative.日本早孕期筛查中宫颈细胞学阳性的危险因素及对阳性细胞学结果的认知:孕妇健康倡议研究报告。
J Int Med Res. 2024 Oct;52(10):3000605241285548. doi: 10.1177/03000605241285548.
5
Human papillomavirus-driven head and neck cancers in Japan during 2008-2009 and 2018-2019: The BROADEN study.2008-2009 年和 2018-2019 年日本 HPV 驱动型头颈部癌症:BROADEN 研究。
Cancer Sci. 2024 Aug;115(8):2808-2818. doi: 10.1111/cas.16230. Epub 2024 Jun 7.
6
The impact of alternate HPV vaccination and cervical screening strategies in Japan: a cost-effectiveness analysis.日本交替人乳头瘤病毒(HPV)疫苗接种与宫颈癌筛查策略的影响:一项成本效益分析
Lancet Reg Health West Pac. 2024 Feb 19;44:101018. doi: 10.1016/j.lanwpc.2024.101018. eCollection 2024 Mar.
7
HPV-Vaccine Hesitancy in Colombia: A Mixed-Methods Study.哥伦比亚对人乳头瘤病毒疫苗的犹豫态度:一项混合方法研究。
Vaccines (Basel). 2022 Jul 27;10(8):1187. doi: 10.3390/vaccines10081187.

本文引用的文献

1
Impact of HPV vaccine hesitancy on cervical cancer in Japan: a modelling study.HPV 疫苗犹豫对日本宫颈癌的影响:建模研究。
Lancet Public Health. 2020 Apr;5(4):e223-e234. doi: 10.1016/S2468-2667(20)30010-4. Epub 2020 Feb 10.
2
Dynamic changes in Japan's prevalence of abnormal findings in cervical cervical cytology depending on birth year.根据出生年份,日本宫颈细胞学异常发现率的动态变化。
Sci Rep. 2018 Apr 4;8(1):5612. doi: 10.1038/s41598-018-23947-6.
3
No association between HPV vaccine and reported post-vaccination symptoms in Japanese young women: Results of the Nagoya study.日本年轻女性中HPV疫苗与接种后报告症状之间无关联:名古屋研究结果
Papillomavirus Res. 2018 Jun;5:96-103. doi: 10.1016/j.pvr.2018.02.002. Epub 2018 Feb 23.
4
Early impact of the Japanese immunization program implemented before the HPV vaccination crisis.在人乳头瘤病毒疫苗危机之前实施的日本免疫计划的早期影响。
Int J Cancer. 2017 Oct 15;141(8):1704-1706. doi: 10.1002/ijc.30855. Epub 2017 Jul 12.
5
Challenges in breast and cervical cancer control in Japan.日本在乳腺癌和宫颈癌防治方面面临的挑战。
Lancet Oncol. 2016 Jul;17(7):e305-e312. doi: 10.1016/S1470-2045(16)30121-8.
6
The Japanese guideline for cervical cancer screening.日本宫颈癌筛查指南。
Jpn J Clin Oncol. 2010 Jun;40(6):485-502. doi: 10.1093/jjco/hyq036. Epub 2010 Apr 30.
7
Do we need a different strategy for HPV screening and vaccination in East Asia?在东亚地区,我们是否需要针对人乳头瘤病毒(HPV)筛查和疫苗接种采取不同的策略?
Int J Cancer. 2006 Dec 1;119(11):2713-5. doi: 10.1002/ijc.22195.

日本在实现消除宫颈癌的全球目标方面所做努力的现状如何?

What is the current status of Japan's efforts to meet global goals and targets to eliminate cervical cancer?

作者信息

Haruyama Rei, Obara Hiromi, Fujita Noriko

机构信息

Bureau of International Health Cooperation, National Center for Global Health and Medicine, Tokyo, Japan.

出版信息

Glob Health Med. 2021 Feb 28;3(1):44-47. doi: 10.35772/ghm.2020.01070.

DOI:10.35772/ghm.2020.01070
PMID:33688595
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7936364/
Abstract

Following the global call to action by the World Health Organization (WHO), the world is currently moving to eliminate cervical cancer as a public health problem. To eliminate the cancer within this century, which is defined as an age-adjusted cervical cancer incidence rate (ASIR) below 4 per 100,000 women, WHO recommends all countries to achieve "90-70-90" targets for human papilloma virus (HPV) vaccination, cervical cancer screening, and treatment of precancer and cancer by 2030. In Japan, ASIR has been rising since the late 1990s to 11.1 per 100,000 women, and this rise is particularly prominent in women of reproductive age. HPV vaccination coverage is as low as 0.3%, largely due to the Governments ongoing suspension of proactive recommendations for the vaccine. Given the absence of centralized, population-based cervical cancer screening program and a nationwide surveillance system for systematic monitoring, the exact screening participation rate and treatment rate are difficult to estimate. A national survey suggested that only around 40% of women between the ages of 20 and 69 years underwent cervical cancer screening within the last two years. National policies and systems for HPV vaccination and screening should be updated in a more efficient way as new evidence and innovations become available. In the wake of powerful global momentum, actions must be taken now to further enhance cervical cancer control and ensure that Japanese girls and women are no longer left behind.

摘要

在世界卫生组织(WHO)发出全球行动呼吁之后,全球目前正朝着消除宫颈癌这一公共卫生问题迈进。为在本世纪内消除宫颈癌(定义为年龄标准化宫颈癌发病率(ASIR)低于每10万名女性4例),WHO建议所有国家到2030年实现人乳头瘤病毒(HPV)疫苗接种、宫颈癌筛查以及癌前病变和癌症治疗的“90-70-90”目标。在日本,自20世纪90年代末以来,ASIR已升至每10万名女性11.1例,且这种上升在育龄女性中尤为显著。HPV疫苗接种覆盖率低至0.3%,这在很大程度上是由于政府持续暂停对该疫苗的积极推荐。鉴于缺乏集中的、基于人群的宫颈癌筛查项目以及用于系统监测的全国性监测系统,确切的筛查参与率和治疗率难以估计。一项全国性调查表明,在过去两年中,年龄在20至69岁之间的女性中只有约40%接受了宫颈癌筛查。随着新证据和创新成果的出现,HPV疫苗接种和筛查的国家政策及系统应以更有效的方式更新。在强大的全球势头推动下,现在必须采取行动进一步加强宫颈癌防控,确保日本的女孩和妇女不再落后。